Status:
NOT_YET_RECRUITING
Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery
Lead Sponsor:
Sir Mortimer B. Davis - Jewish General Hospital
Collaborating Sponsors:
Lady Davis Institute
McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions:
Head Neck Cancer
Xerostomia Following Radiotherapy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Head and neck cancer care, including tumors of the mouth, nose, throat and voice box, often requires radiation for cure to be achieved. Despite advances in radiation, 40% to 60% of patients experience...
Eligibility Criteria
Inclusion
- Newly diagnosis AJCC 8th edition Stage III/IVa mucosal head and neck squamous cell carcinoma requiring definitive radiotherapy (with or without chemotherapy).
Exclusion
- Previous radiation to the head and neck
- Previous treatment for head and neck cancer
- Personal history of xerostomia
- Hypersensitivity to onabotulinumtoxinA
- Previous major salivary gland surgery
- Previous exposure to radioactive iodine therapy
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06530524
Start Date
October 1 2024
End Date
December 1 2027
Last Update
July 31 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill University
Montreal, Quebec, Canada